The clinical effectiveness agency for England and Wales says that a price cut will allow it to recommend the drug nilotinib for the treatment of chronic myeloid leukemia when standard-dose imatinib is unsuitable or ineffective.Nilotinib (Tasigna), one of three treatment options being evaluated by the National Institute for Health and Clinical Excellence for this patient group, was the only one that made the cut. In May, NICE had issued draft guidance rejecting nilotinib, along with two comparable...